CRSwNP
-
Upstream Bio Announces Conference Call and Webcast to Discuss Top-Line Phase 2 VIBRANT Trial Results for Verekitug in CRSwNP Patients
Upstream Bio (UPB) will announce Phase 2 VIBRANT trial top-line data for verekitug in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) on September 2, 2025. The global, placebo-controlled study evaluated verekitug, a monoclonal antibody targeting TSLP, administering 100 mg subcutaneously every 12 weeks. The primary endpoint is the change in endoscopic nasal polyp score (NPS) at Week 24. A conference call and webcast will be held at 8:00 a.m. ET to discuss the results. Verekitug is unique for targeting TSLP, a key driver of inflammatory responses.
-
Dupixent® (dupilumab) Outperforms Xolair® (omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Patients with Asthma: First-of-its-Kind Phase 4 Head-to-Head Respiratory Trial
The EVEREST Phase 4 trial presented at the 2025 EAACI conference demonstrated that Dupixent outperformed Xolair in treating chronic rhinosinusitis with nasal polyps and asthma. The study showed superior results for Dupixent across all endpoints for both conditions, including nasal polyp size reduction, improved smell, and enhanced lung function. This head-to-head comparison represents a significant milestone in respiratory disease treatment.
